Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Node Positive HER2 Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT05034393
What this trial is testing

Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil

Who this might be right for
Breast Cancer
Latin American Cooperative Oncology Group 308
Early research (Phase 1)Study completedNCT01857193
What this trial is testing

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 132
Not applicableNot Yet RecruitingNCT07309887
What this trial is testing

This Clinical Trial is a Retrospective, Multicenter Cohort Study Evaluating the Real-world Characteristics and Risk of Disease Recurrence in Hormone Receptor-positive, HER2-negative Early Breast Cancer.

Who this might be right for
Early Breast Cancer
Samsung Medical Center 100,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT04576455
What this trial is testing

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Who this might be right for
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 303
Testing effectiveness (Phase 2)UnknownNCT03638648
What this trial is testing

Recurrence Score-guiding Chemotherapy in Non-pCR HR Positive HER2 Negative Breast Cancer After Neoadjuvant Therapy

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 80
Testing effectiveness (Phase 2)Looking for participantsNCT07498478
What this trial is testing

Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

Who this might be right for
Breast Cancer
TransThera Sciences (Nanjing), Inc. 94
Early research (Phase 1)Study completedNCT02605915
What this trial is testing

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Who this might be right for
HER2-Positive Metastatic Breast CancerHER2-Negative Metastatic Breast CancerLocally Advanced or Early Breast Cancer
Hoffmann-La Roche 98
Early research (Phase 1)Study completedNCT06570031
What this trial is testing

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

Who this might be right for
Hormone Receptor-positive Breast CancerHER2-negative Breast CancerMetastatic Breast Cancer+1 more
Ono Pharmaceutical Co., Ltd. 46
Not applicableStudy completedNCT05399329
What this trial is testing

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

Who this might be right for
Breast Cancer
Pfizer 693
Testing effectiveness (Phase 2)Study completedNCT03213041
What this trial is testing

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+4 more
Northwestern University 12
Early research (Phase 1)WithdrawnNCT04756505
What this trial is testing

Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Hormone Receptor Positive Breast AdenocarcinomaMetastatic Breast Carcinoma+2 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT06938724
What this trial is testing

Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer

Who this might be right for
Breast Neoplasm Malignant Female
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 152
Early research (Phase 1)WithdrawnNCT04142554
What this trial is testing

Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmsTriple Negative Breast Cancer+1 more
UNC Lineberger Comprehensive Cancer Center
Not applicableUnknownNCT04030728
What this trial is testing

Implementing Patients´ Competence in Oral Breast Cancer Therapy

Who this might be right for
Metastatic Breast CancerAdvanced Breast Cancer
Onco Medical Consult GmbH 212
Testing effectiveness (Phase 2)Study completedNCT03227328
What this trial is testing

CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO

Who this might be right for
Hormone Receptor Positive Breast CancerMetastatic Breast CancerHormone Receptor Negative Breast Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 52
Not applicableEnded earlyNCT06126003
What this trial is testing

Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.

Who this might be right for
Breast Cancer
BioCorteX Inc 2
Post-approval studies (Phase 4)Looking for participantsNCT05362760
What this trial is testing

Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management

Who this might be right for
Hormone Receptor-positive Metastatic Breast CancerHER2-negative Metastatic Breast Cancer
Prof. Wolfgang Janni 300
Testing effectiveness (Phase 2)UnknownNCT06133088
What this trial is testing

Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.

Who this might be right for
Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
Zhejiang Cancer Hospital 53
Testing effectiveness (Phase 2)Looking for participantsNCT07647016
What this trial is testing

Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study

Who this might be right for
Breast Cancer
Fudan University 53
Testing effectiveness (Phase 2)Looking for participantsNCT05985655
What this trial is testing

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic AdenocarcinomaNon-small Cell Lung Cancer (NSCLC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 230
Next Page